Literature DB >> 23118655

Pharmacogenomics of adverse effects of anti-leukemic agents in children.

Mary V Relling1.   

Abstract

Entities:  

Keywords:  clinical pharmacology; pharmacogenomics

Year:  2012        PMID: 23118655      PMCID: PMC3428190          DOI: 10.5863/1551-6776-17.1.7

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


× No keyword cloud information.
  28 in total

Review 1.  Acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; Mary V Relling; James R Downing
Journal:  N Engl J Med       Date:  2004-04-08       Impact factor: 91.245

Review 2.  Pharmacogenetics and cancer therapy.

Authors:  M V Relling; T Dervieux
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

3.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.

Authors:  W E Evans; Y Y Hon; L Bomgaars; S Coutre; M Holdsworth; R Janco; D Kalwinsky; F Keller; Z Khatib; J Margolin; J Murray; J Quinn; Y Ravindranath; K Ritchey; W Roberts; Z R Rogers; D Schiff; C Steuber; F Tucci; N Kornegay; E Y Krynetski; M V Relling
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.

Authors:  M V Relling; M L Hancock; J M Boyett; C H Pui; W E Evans
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

5.  Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.

Authors:  Lisa R Treviño; Noriko Shimasaki; Wenjian Yang; John C Panetta; Cheng Cheng; Deqing Pei; Diana Chan; Alex Sparreboom; Kathleen M Giacomini; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

6.  Late-onset delayed excretion of methotrexate.

Authors:  Jennifer L Pauley; John Carl Panetta; Jeffrey Schmidt; Nancy Kornegay; Mary V Relling; Ching-Hon Pui
Journal:  Cancer Chemother Pharmacol       Date:  2004-05-18       Impact factor: 3.333

7.  Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

Authors:  Mary V Relling; Wenjian Yang; Soma Das; Edwin H Cook; Gary L Rosner; Michael Neel; Scott Howard; Raul Ribeiro; John T Sandlund; Ching-Hon Pui; Sue C Kaste
Journal:  J Clin Oncol       Date:  2004-10-01       Impact factor: 44.544

8.  Patient characteristics associated with high-risk methotrexate concentrations and toxicity.

Authors:  M V Relling; D Fairclough; D Ayers; W R Crom; J H Rodman; C H Pui; W E Evans
Journal:  J Clin Oncol       Date:  1994-08       Impact factor: 44.544

9.  Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.

Authors:  M L Garré; M V Relling; D Kalwinsky; R Dodge; W R Crom; M Abromowitch; C H Pui; W E Evans
Journal:  J Pediatr       Date:  1987-10       Impact factor: 4.406

10.  A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.

Authors:  E Y Krynetski; J D Schuetz; A J Galpin; C H Pui; M V Relling; W E Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.